Scribd Logo
Upload

Welcome to Scribd!

  • 26 views

    Project Prepared and Presented By:: Jinia Biswas Sruti Jain Vibhav Kaushal

    Uploaded by

    manisha sonawane
    Sun Pharmaceutical Industries Ltd is a major pharmaceutical company based in India. It was established in 1983 and went public in 1994. Since then it has grown significantly through acquisitions and now ranks among the largest pharmaceutical companies in India. It has received several awards and accolades for its business performance. In recent years, it has made major acquisitions in the US pharmaceutical market to expand its global operations.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Project Prepared and Presented By:: Jinia Biswas Sruti Jain Vibhav Kaushal

    Uploaded by

    manisha sonawane
    26 views19 pages
    Sun Pharmaceutical Industries Ltd is a major pharmaceutical company based in India. It was established in 1983 and went public in 1994. Since then it has grown significantly through acquisitions and now ranks among the largest pharmaceutical companies in India. It has received several awards and accolades for its business performance. In recent years, it has made major acquisitions in the US pharmaceutical market to expand its global operations.

    Original Description:

    sun pharma .ppt-annual report 2012-2013

    Original Title

    sunpharmappt-annual report 2012-2013

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Sun Pharmaceutical Industries Ltd is a major pharmaceutical company based in India. It was established in 1983 and went public in 1994. Since then it has grown significantly through acquisitions and now ranks among the largest pharmaceutical companies in India. It has received several awards and accolades for its business performance. In recent years, it has made major acquisitions in the US pharmaceutical market to expand its global operations.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    26 views19 pages

    Project Prepared and Presented By:: Jinia Biswas Sruti Jain Vibhav Kaushal

    Uploaded by

    manisha sonawane
    Sun Pharmaceutical Industries Ltd is a major pharmaceutical company based in India. It was established in 1983 and went public in 1994. Since then it has grown significantly through acquisitions and now ranks among the largest pharmaceutical companies in India. It has received several awards and accolades for its business performance. In recent years, it has made major acquisitions in the US pharmaceutical market to expand its global operations.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 19

    Project prepared and

    presented by:

    Jinia Biswas
    Sruti Jain
    Vibhav Kaushal
    HISTORY
    • 1983 – Sun Pharma established with five psychiatry
    products and two person marketing team at Vapi, Gujarat.
    • 1994 – Sun Pharma went public in an issue that was
    oversubscribed 55 times.
    • 1989 – Exports to neighbouring countries began.
    • 2000 – Sun Pharma ranked 5th largest pharmaceutical
    company in India.
    • 2007 – Sun Pharma demerged into a separate entity Sun
    Pharma Advanced Research Company, the first research
    company to get listed on stock exchanges in India.
    • 2012 – Major acuisitions in US completed.
    BOARD OF DIRECTORS
    Chairman – Israel Makov
    Managing Director – Dilip S. Shanghvi
    Executive Director – Sudhir V. Valia, Sailesh
    Desai
    Non-executive independent director –
    Hasmukh Shah, Keki M. Mistry, Ashwin
    Dani, S. Mohanchand Dadha.
    AWARDS 2012
     Business Leadership Of The Year -
    Pharmaceutical – NDTV Profit
     Most outstanding Company Of The Year –
    CNBC TV 18 India Business Leader Award
     Listed on World’s 100 Most Innovative
    Companies – Forbes
     Listed on Asia’s Fab 50 - Forbes
    ACUISITIONS & JOINT VENTURES
    Generic Business of URL Pharma , United
    States
    Dusa Pharmaceuticals Inc, United States
    Joint Venture with MSD
    Acquired Caraco Pharmaceutical Laboratories
    Ltd
    Acquired Taro Pharmaceutical Industries Ltd
    Acquired Inwood Laboratories Incorprated
    SHARE PRICE
    As on 26th November, 2013 :
    BSE Rs 587.55, 7.00(+1.21%) , Volume 17,147

    As on 26th November, 2013 :


    NSE Rs 587.70, 6.85(+1.18%), Volume
    150,672
    SUN PHARMA INDUSTRIES STOCK
    PRICE
    P/E 652.30 P/C(Based on standalone
    numbers) 443.17
    BOOK VALUE(Rs) 41.64 PRICE BOOK(Based on
    standalone numbers) 13.94
    DIVIDEND(%) 250.00% DIVIDEND YIELD(%) 0.43%

    MARKET LOT 1 FACE VALUE(Rs) 1

    INDUTSRY P/E 32.03 DELIVERABLES(%) 69.85


    CONTRIBUTION TO SENSEX
    COMPANY INDUSTRY LAST CHANGE MARKET CONTRIBUT
    NAME PRICE Rs (%) CAPITALIZATION ON
    (CRORES)

    SUN PHARMA PHARMACEUTICAL 587.70 7.15 1.23 48688.92 8.56

    CIPLA DO 390.75 3.45 0.89 20393.20 2.68

    DR.REDDY’S DO 2438.00 -1.30 -0.05 31102.74 -0.24


    LAB
    CONTRIBUTION TO NIFTY
    COMPANY LAST PRICE CHANGE MARKET CONTRIBUTION
    Rs (%) CAP(CRORES)

    SUN PHARMA 589.80 8.95 1.54 122,157.25 2.07

    LUPIN 853.50 2.90 0.34 38251.99 0.15

    CIPLA 390.60 3.50 0.90 31362.11 0.31

    RANBAXY 428.00 3.05 0.72 18110.47 0.14

    DR.REDDY’S 2446.80 6.65 0.27 41620 0.13


    LAB
    DIVIDEND HISTORY
    Financial Interim/F Rate of Dividend Face Book Date of
    Year inal Dividend per Value Closure declarati
    equity of
    share(Rs From To dividend

    2007- Final 210% 10.50 Rs 5 27/08/08 6/09/08 6/09/08


    2008
    2008- Final 275% 13.75 Rs 5 25/08/09 5/09/09 11/09/09
    2009
    2009- Final 275% 13.75 Rs 5 14/09/10 24/09/10 24/09/10
    2010
    2010- Final 350% 3.50 Re 1 6/09/11 16/09/11 16/09/11
    2011
    2011- Interim 425% 4.25 Re 1 16/08/12 Record 10/18/12
    2012 Date
    TREND ANALYSIS
    KEY PERFORMANCE INDICATORS
    INDICATOR/ TOTAL INCOME PROFIT FOR RESERVE & EARNINGS NET BLOCK
    YEAR THE YEAR SURPLUS PER SHARE
    2008-2009 44808 18780 69414 87.8 14625

    2009-2010 42123 13470 77254 65.2 15328

    2010-2011 60827 18161 93798 17.5 25214

    2011-2012 84910 26567 121322 25.7 29295

    2012-2013 116880 29831 148862 28.8 45145


    21st ANNUAL REPORT FOR THE YEAR
    ENDED MARCH 31, 2013
    Particulars Year ended March Year ended March
    31,2013(Rs in 31, 2012(Rs in
    million) million)
    Total Income 26,683 43,584
    Profit After Tax 5,166 16,975
    Dividend on Equity Shares 5,178 4,401
    Corporate Dividend Tax 880 714
    Transfer to various reserves 520 2,000
    Amount of dividend per equity share 2.50 4.25
    of Re 1 each
    Book Value per equity share of Re 1 75 76
    each
    EXPENDITURE ON R & D Year ended March 31, Year ended March 31,
    2013(Rs in million) 2012(Rs in million)

    Capital 377.2 352.1

    Revenue 2725 1831.9

    Total 3102.2 2184

    Total R&D as a % of 13.8% 9.1%


    Total Turnover
    CURRENT NEWS ON SUN PHARMA
    • Sun Pharmaceutical Industries Ltd gained 1 per cent after
    unit Taro Pharmaceutical Industries announced the start of a
    tender offer to buy back up to $200 million of its ordinary
    shares.

    • Sun Pharma's stake in Taro will go up to more than 69 per


    cent from 66 per cent should the buyback be fully
    subscribed.

    • MUMBAI: The impregnable walls around top


    defensive stocks such as ITC and Sun Pharma have
    cracked, as they have lost nearly 10% from their October
    peaks against NSE Nfity's fall of just a little over 1%. These
    stocks are among the biggest losers in benchmark Nfity
    during the past month.
    • Pharma leader Sun Pharma is trading at 40 times, which is the
    highest among its peers.

    • Drug Controller General of India has ordered Sun


    Pharmaceutical, the country's largest drug maker by m-cap, to
    suspend clinical research activities at its Mumbai based bio-
    analytical laboratory, a move that could slow down its regulatory
    filings in India and overseas as well.

    • The company has upped its revenue growth guidance to 25% for
    FY14 over the previously announced range of 18-20%, but analysts
    are sceptical of sustainability of margins.
    Campus http://www.unitedworld.edu.in/
    Ahmedabad Campus: Karnavati Knowledge Village,
    A/907,Uvarsad, S.G.Highway, Gandhinagar

    Kolkata Campus: Infinity Benchmark Tower 10th Floor, Plot -


    G1, Block - EP& GP, Sec - V, Salt Lake, Kolkata.

    Reg. Office: 407, Zodiac Square, 4th Floor Opp. Gurudwara, S.G.
    Road, Bodakdev, Ahmedabad.

    You might also like